Patient Advocacy

February 28, 2023 The Importance of Self-Advocacy: Supporting Patients and Caregivers in Their Rare Disease ... Rare Disease Day unites the community to spread awareness and support the millions of people worldwide living with with a rare disease. Read More ›
December 16, 2021 Guest Post: Creating Connections to Support the hATTR Amyloidosis Community Susanne Berglund is the Chancellor of FAMY Norrbotten, an amyloidosis patient advocacy group reflects on the importance of making connections to support... Read More ›
April 15, 2021 Guest Post: Partnering to Make a Positive Difference for People with Kidney Disease LaVarne Burton, President and CEO of the American Kidney Fund talks about the importance of partnerships... Read More ›
February 23, 2021 Rare Disease Day 2021: Rare Is Many. Rare Is Strong. Rare Is Proud. While some aspects of living with a rare disease are similar, there is no singular shared experience. There is, however, a common sentiment among those... Read More ›
December 7, 2020 Alnylam Releases 2nd Annual Patient Access Philosophy Report The 2020 Alnylam Patient Access Philosophy Report details Alnylam's progress against key metrics related to patient access to its innovative RNAi therapeutics. Read More ›
October 1, 2020 A New European Biotech Social Pact The European Pact builds on Alnylam’s own pledge, encouraging biotech companies to be a force for good in partnering with European authorities, citizens and... Read More ›
August 3, 2020 How to Evaluate a Medicine for the Treatment of an Ultra-rare Disease Such as PH1 For a new medicine to become available, it needs to undergo stringent testing in clinical trials to evaluate its safety and, importantly, its efficacy... Read More ›
June 2, 2020 Announcing the 2019-2020 Advocacy for Impact Grant Recipients The Alnylam 2019-2020 Advocacy for Impact grant recipients come from five countries across three continents, and will receive grants totaling USD $270,000.00... Read More ›
May 6, 2020 Navigating the Winding Road to Drug Approvals Learn about the winding road and key members involved in getting a new drug approved. Read More ›

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site